NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
84.86
+0.39 (+0.46%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close84.47
Open84.43
Bid0.00 x 0
Ask0.00 x 0
Day's Range84.30 - 84.95
52 Week Range69.53 - 86.90
Volume1,281,851
Avg. Volume1,704,795
Market Cap201.015B
Beta0.73
PE Ratio (TTM)30.23
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.72 (3.21%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
    Zacks11 hours ago

    CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

    The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

  • Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
    Zacks14 hours ago

    Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

    Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

  • Capital Cube14 hours ago

    ETFs with exposure to Novartis AG : December 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novartis AG Here are 5 ETFs with the largest exposure to NVS-US. Comparing the performance and risk of Novartis AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
    Investor's Business Daily15 hours ago

    Beware: Price Wars For Big Pharma, Biotech Companies On Horizon

    The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.

  • Benzinga3 days ago

    ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

    The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was ...

  • Reuters3 days ago

    Novartis generics arm says may sell or end some products

    Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. "In response to high price pressure, we are optimizing our U.S. portfolio. "As we continue to refine our portfolio, it is clear that the U.S. market is a very important market for Sandoz and will continue to be in the future," it added.

  • Novartis Announces Positive Data on Sickle Cell Disease Drug
    Zacks3 days ago

    Novartis Announces Positive Data on Sickle Cell Disease Drug

    Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.

  • ASH 2017: CAR-T Wallops Blood Cancer
    Motley Fool4 days ago

    ASH 2017: CAR-T Wallops Blood Cancer

    The ability to beat back blood cancer using gene therapy offers a significant opportunity to improve patient treatment.

  • Novartis Reports Updated Results from Kymriah's JULIET Study
    Zacks4 days ago

    Novartis Reports Updated Results from Kymriah's JULIET Study

    Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.

  • What's Causing Juno Therapeutics Shares to Tumble 11.9% Today
    Motley Fool5 days ago

    What's Causing Juno Therapeutics Shares to Tumble 11.9% Today

    Investors are selling shares following an important presentation at a key industry conference.

  • Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
    Zacks5 days ago

    Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

    Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.

  • Barrons.com5 days ago

    Gilead Sciences: Better Data, Better Stock?

    Shares of Gilead Sciences (GILD) are higher on Monday, building on its strength from Friday when it announced its acquisition of Cell Design Labs. Gilead got a boost today from its its presentation at the American Society of Hematology's (ASH) annual meeting, where it and other companies provided update on their CAR-T therapies aimed at cancer. BMO Capital Markets' M. Ian Somaiya wrote that the news was good for Gilead and its peers: Updates from the three leading trials of CD-19 CAR-T therapy in DLBCL (GILD's Yescarta, Juno Therapeutics' (JUNO) JCAR017, Novartis' (NVS) Kymriah) raise the bar yet again for CAR-Ts.

  • MarketWatch5 days ago

    These defensive stocks make the cut as one of Morgan Stanley’s key picks for 2018

    Switzerland’s stocks are changing hands below their typical premium, the Swiss franc appears poised to slide further against the euro, and earnings growth looks good.

  • Reuters5 days ago

    Novartis CAR-T therapy leads to durable response in lymphoma study

    Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday. Among 46 patients with at least six months of follow-up after treatment with Novartis' Kymriah for diffuse large B-cell lymphoma (DLBCL), 30 percent still had a complete response, meaning no detectable sign of cancer, with another 7 percent achieving a partial response.

  • Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
    Reuters8 days ago

    Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

    Prosecutors in Rome have been looking into charges the two companies colluded to discredit eye disease drug Avastin by emphasizing its potential side effects in order to boost sales of Lucentis, a more expensive alternative which offers similar treatment. Both Avastin and Lucentis are manufactured by Roche but Lucentis is marketed by Novartis outside the United States.

  • Pfizer Reports Updated Data from Phase III Study on Ibrance
    Zacks8 days ago

    Pfizer Reports Updated Data from Phase III Study on Ibrance

    Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.

  • Forbes9 days ago

    In Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves Symptoms

    So far in this trial, ribociclib extended PFS by around a year (23.8 vs. 13.0 months). That’s a dramatic and early result.

  • Market Realist10 days ago

    Analysts’ Recommendations for GlaxoSmithKline in November 2017

    Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.

  • Australian watchdog takes GlaxoSmithKline, Novartis units to court
    Reuters10 days ago

    Australian watchdog takes GlaxoSmithKline, Novartis units to court

    The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

  • Market Realist11 days ago

    Novartis on the Street: Analyst Recommendations in November

    Of the four analysts tracking Novartis ADR, two recommend a “buy,” while two recommend a “hold.” None recommends a “sell.”

  • Market Realist12 days ago

    Behind Novartis’s Developments as of November 2017

    Novartis reported a 2% YoY rise in revenues at constant exchange rates to ~$12.4 billion in 3Q17. Here, we'll look at the company's key developments.

  • Market Realist12 days ago

    Inside Novartis’s Alcon Performance in 3Q17

    Alcon reported revenues of $1.53 billion in 3Q17, which was 6% higher YoY (year-over-year), compared with $1.44 billion in 3Q16.

  • Market Realist12 days ago

    GlaxoSmithKline’s Valuation in November 2017

    In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.

  • MarketWatch13 days ago

    Mylan and Teva stocks rise on report about Amazon’s pharmacy aims

    Shares of generic drug manufacturers are rising on a report stating that Amazon.com held talks with Mylan and Novartis’ Sandoz about entering the pharmacy business, while shares of distributors and drugstores ...

  • Market Realist14 days ago

    Inside Novartis’s Innovative Medicines Business in 3Q17

    This segment contributed ~66.9% of Novartis's total revenues in 3Q17, reporting ~$8.3 billion, which represents 2% YoY (year-over-year).